Drug intelligence / Profile preview

3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE

Development stage: Unknown
Modality: Small Molecules

Overview

3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE is a synthetic organic compound with the molecular formula C23H17F3N4O. It is characterized by a benzamide core structure substituted with a quinazoline group and a trifluoromethylphenyl group. While its chemical structure is well-defined and it has a PubChem Compound ID (CID 15991573), detailed information regarding its specific biological activity, mechanism of action, or development status is not readily available in public databases. Its presence in DrugBank (DB06925) suggests potential pharmaceutical interest.

Targets

nsp16 (Non-structural protein 16/Non-structural protein 10 complex)Tyrosine kinaseDDR1 (Discoidin domain receptor 1)

Beyond the preview

Go deeper on 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE.

Explore the full profile